{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:46:25Z","timestamp":1792269985861,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biotechnology Reports"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.btre.2025.e00940","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T16:18:19Z","timestamp":1764692299000},"page":"e00940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pathogenesis and advances in immunotherapy for type 1 diabetes treatment"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9068-8798","authenticated-orcid":false,"given":"Tran Chi","family":"Linh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Khanh","family":"Dung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9911","key":"10.1016\/j.btre.2025.e00940_bib0001","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","article-title":"Type 1 diabetes","volume":"383","author":"Atkinson","year":"2014","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.btre.2025.e00940_bib0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/dc19-0880","article-title":"Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes","volume":"43","author":"Battaglia","year":"2020","journal-title":"Diabetes care"},{"issue":"1084","key":"10.1016\/j.btre.2025.e00940_bib0003","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/postgradmedj-2015-133281","article-title":"Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective","volume":"92","author":"Zaccardi","year":"2016","journal-title":"Postgrad. Med. J."},{"issue":"315","key":"10.1016\/j.btre.2025.e00940_bib0004","doi-asserted-by":"crossref","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.btre.2025.e00940_bib0005","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11892-017-0878-z","article-title":"Combination immunotherapy for type 1 diabetes","volume":"17","author":"Bone","year":"2017","journal-title":"Curr. Diab. Rep."},{"issue":"4","key":"10.1016\/j.btre.2025.e00940_bib0006","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.smim.2006.03.008","article-title":"Role of PTPN22 in type 1 diabetes and other autoimmune diseases","volume":"18","author":"Bottini","year":"2006","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.btre.2025.e00940_bib0007","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/POC.0000000000000125","article-title":"Type 1 Diabetes \u2013 A Clinical Perspective","volume":"16","author":"Kahanovitz","year":"2017","journal-title":"Point Care"},{"key":"10.1016\/j.btre.2025.e00940_bib0008","article-title":"Type 1 Diabetes, in: StatPearls, StatPearls Publishing","author":"Lucier","year":"2025","journal-title":"Treasure Island (FL)"},{"key":"10.1016\/j.btre.2025.e00940_bib0009","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00125-018-4763-3","article-title":"Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989\u20132013: a multicentre prospective registration study","volume":"62","author":"Patterson","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.btre.2025.e00940_bib0010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11892-025-01595-1","article-title":"From Prediction to Prevention: The Intricacies of Islet Autoantibodies in Type 1 Diabetes","volume":"25","author":"Khine","year":"2025","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.btre.2025.e00940_bib0011","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3390\/life15101579","article-title":"Continuous Glucose Monitoring in People at High Risk of Diabetes and Dysglycaemia: Transforming Early Risk Detection and Personalised Care","volume":"15","author":"Liarakos","year":"2025","journal-title":"Life"},{"issue":"9","key":"10.1016\/j.btre.2025.e00940_bib0012","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.4049\/jimmunol.1100272","article-title":"Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function","volume":"188","author":"Garg","year":"2012","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.btre.2025.e00940_bib0013","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.btre.2025.e00940_bib0014","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/pedi.13097","article-title":"Markers of cholesterol synthesis are elevated in adolescents and young adults with type 2 diabetes","volume":"21","author":"Semova","year":"2020","journal-title":"Pedi. Diab."},{"key":"10.1016\/j.btre.2025.e00940_bib0015","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2337\/db07-1331","article-title":"for the Type 1 Diabetes Genetics Consortium, HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk: Analysis of the Type 1 Diabetes Genetics Consortium Families","volume":"57","author":"Erlich","year":"2008","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.btre.2025.e00940_bib0016","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.2337\/dc23-0675","article-title":"Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves \u03b2-cell function","volume":"46","author":"Herold","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.btre.2025.e00940_bib0017","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1186\/s13104-018-3875-7","article-title":"The PTPN22 C1858T (R620W) functional polymorphism in inflammatory bowel disease","volume":"11","author":"Zaid","year":"2018","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.btre.2025.e00940_bib0018","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.molmed.2008.04.002","article-title":"The molecular genetics of type 1 diabetes: new genes and emerging mechanisms","volume":"14","author":"Ounissi-Benkalha","year":"2008","journal-title":"Trends. Mol. Med"},{"key":"10.1016\/j.btre.2025.e00940_bib0019","doi-asserted-by":"crossref","first-page":"513","DOI":"10.14348\/molcells.2022.2056","article-title":"Current Understanding of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Signaling in T-Cell Biology and Disease Therapy","volume":"45","author":"Kim","year":"2022","journal-title":"Mol. Cells"},{"issue":"24","key":"10.1016\/j.btre.2025.e00940_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417320","article-title":"Challenges of CRISPR\/cas-based cell therapy for type 1 diabetes: how not to engineer a \u201cTrojan horse","volume":"24","author":"Karpov","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.btre.2025.e00940_bib0021","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41587-023-02055-5","article-title":"Encapsulated stem cell\u2013derived \u03b2 cells exert glucose control in patients with type 1 diabetes","volume":"42","author":"Keymeulen","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.btre.2025.e00940_bib0022","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-8587(21)00170-4","article-title":"Restoring normal islet mass and function in type 1 diabetes through regenerative medicine and tissue engineering","volume":"9","author":"Krentz","year":"2021","journal-title":"Lancet. Diabetes Endocrinol."},{"key":"10.1016\/j.btre.2025.e00940_bib0023","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1016\/S0140-6736(16)30507-4","article-title":"Environmental risk factors for type 1 diabetes","volume":"387","author":"Rewers","year":"2016","journal-title":"The Lancet."},{"key":"10.1016\/j.btre.2025.e00940_bib0024","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00125-021-05398-3","article-title":"Current and future therapies for type 1 diabetes","volume":"64","author":"von Scholten","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.btre.2025.e00940_bib0025","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00005-016-0452-4","article-title":"Apportioning blame: autoreactive CD4+ and CD8+ T cells in type 1 diabetes","volume":"65","author":"Varela-Calvino","year":"2017","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.btre.2025.e00940_bib0026","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00125-017-4377-1","article-title":"Regulatory T cell dysfunction in type 1 diabetes: what\u2019s broken and how can we fix it?","volume":"60","author":"Hull","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.btre.2025.e00940_bib0027","doi-asserted-by":"crossref","first-page":"e1122","DOI":"10.1002\/cti2.1122","article-title":"Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets","volume":"9","author":"Lu","year":"2020","journal-title":"Clin. Transl. Immun."},{"key":"10.1016\/j.btre.2025.e00940_bib0028","doi-asserted-by":"crossref","first-page":"101565","DOI":"10.1016\/j.molmet.2022.101565","article-title":"Beta cell and immune cell interactions in autoimmune type 1 diabetes: How they meet and talk to each other","volume":"64","author":"Scherm","year":"2022","journal-title":"Mol. Metab."},{"key":"10.1016\/j.btre.2025.e00940_bib0029","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41420-019-0217-z","article-title":"Soluble FAS ligand is not required for pancreatic islet inflammation or beta-cell destruction in non-obese diabetic mice","volume":"5","author":"Trivedi","year":"2019","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.btre.2025.e00940_bib0030","doi-asserted-by":"crossref","first-page":"474","DOI":"10.2337\/cd23-0033","article-title":"Teplizumab: The First Treatment to Delay the Progression of Type 1 Diabetes","volume":"41","author":"Goldman","year":"2023","journal-title":"Clin. Diabet."},{"key":"10.1016\/j.btre.2025.e00940_bib0031","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/s41591-024-03115-2","article-title":"Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial","volume":"30","author":"Tatovic","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.btre.2025.e00940_bib0032","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","article-title":"Baricitinib and \u03b2-Cell Function in Patients with New-Onset Type 1 Diabetes","volume":"389","author":"Waibel","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.btre.2025.e00940_bib0033","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1210\/endrev\/bnaa028","article-title":"Progress in translational regulatory T cell therapies for type 1 diabetes and islet transplantation","volume":"42","author":"Marfil-Garza","year":"2021","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.btre.2025.e00940_bib0034","doi-asserted-by":"crossref","first-page":"108524","DOI":"10.1016\/j.jdiacomp.2023.108524","article-title":"The promise of CRISPR\/Cas9 technology in diabetes mellitus therapy: How gene editing is revolutionizing diabetes research and treatment","volume":"37","author":"Cheng","year":"2023","journal-title":"J. Diabet. Complicat."},{"key":"10.1016\/j.btre.2025.e00940_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1349601","article-title":"The IFIH1-A946T risk variant promotes diabetes in a sex-dependent manner","volume":"15","author":"Stock","year":"2024","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.btre.2025.e00940_bib0036","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3390\/jcm14020383","article-title":"Pre-type 1 diabetes in adolescents and teens: screening, nutritional interventions, beta-cell preservation, and psychosocial impacts","volume":"14","author":"Sundheim","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.btre.2025.e00940_bib0037","doi-asserted-by":"crossref","first-page":"101570","DOI":"10.1016\/j.omtm.2025.101570","article-title":"Effects of CRISPR-Cas9-mediated FOXP3 knockout on CAR T cell potency","volume":"33","author":"Peter","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.btre.2025.e00940_bib0038","doi-asserted-by":"crossref","first-page":"1533748","DOI":"10.3389\/fendo.2025.1533748","article-title":"Teplizumab: a promising intervention for delaying type 1 diabetes progression","volume":"16","author":"Saleem","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.btre.2025.e00940_bib0039","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.3390\/jcm12134527","article-title":"A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience","volume":"12","author":"Taylor","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.btre.2025.e00940_bib0040","first-page":"1272","article-title":"Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies","volume":"13","author":"Andreescu","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.btre.2025.e00940_bib0041","first-page":"345","article-title":"Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential, Sig Transduct Target","volume":"10","author":"Wang","year":"2025","journal-title":"Ther"},{"issue":"6","key":"10.1016\/j.btre.2025.e00940_bib0042","doi-asserted-by":"crossref","first-page":"952","DOI":"10.4103\/2230-8210.102998","article-title":"Regulatory T cells in children with recently diagnosed type 1 diabetes","volume":"16","author":"Zahran","year":"2012","journal-title":"Indian J. Endocrinol. Metab."},{"issue":"23","key":"10.1016\/j.btre.2025.e00940_bib0043","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1001\/jama.2013.6285","article-title":"Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children","volume":"309","author":"Ziegler","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.btre.2025.e00940_bib0044","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3390\/biology11040608","article-title":"Environmental factors and the risk of developing type 1 diabetes-old disease and new data","volume":"11","author":"Zorena","year":"2022","journal-title":"Biology"}],"updated-by":[{"DOI":"10.1016\/j.btre.2026.e00983","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000}}],"container-title":["Biotechnology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215017X25000670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215017X25000670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:01:54Z","timestamp":1791475314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2215017X25000670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":44,"alternative-id":["S2215017X25000670"],"URL":"https:\/\/doi.org\/10.1016\/j.btre.2025.e00940","relation":{},"ISSN":["2215-017X"],"issn-type":[{"value":"2215-017X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenesis and advances in immunotherapy for type 1 diabetes treatment","name":"articletitle","label":"Article Title"},{"value":"Biotechnology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.btre.2025.e00940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"e00940"}}